PTCHD2 Inhibitors
PTCHD2 inhibitors are a class of chemical compounds designed to selectively inhibit the activity of the PTCHD2 protein, which is part of the Patched (PTCH) family. This family is characterized by its role in the Hedgehog (Hh) signaling pathway, a crucial regulator of cellular development and differentiation. PTCHD2 is structurally related to PTCH1, a well-known receptor for the Hedgehog ligand, and is believed to play a role in modulating the Hh pathway. PTCHD2 inhibitors typically function by binding to the PTCHD2 protein and blocking its interaction with other proteins or signaling components, which leads to alterations in pathway activity. By inhibiting PTCHD2, these compounds can disrupt the downstream effects of the pathway, which may include changes in gene expression, cellular proliferation, and differentiation processes.
The chemical structure of PTCHD2 inhibitors varies widely, as multiple classes of molecules have been developed to target the protein with varying degrees of specificity and potency. Some of these inhibitors are small molecules designed to penetrate cells and interact directly with PTCHD2. Structural features of these molecules often include lipophilic and hydrophilic regions to ensure adequate bioavailability and target engagement. The development of PTCHD2 inhibitors requires careful optimization to enhance their selectivity toward PTCHD2 over other PTCH family members or unrelated proteins, reducing potential off-target effects. The identification and characterization of these inhibitors involve extensive biochemical and structural studies to determine their binding modes, efficacy, and mechanisms of action at the molecular level. Understanding how PTCHD2 inhibitors interact with their target has important implications for studying the regulation of the Hedgehog pathway and the role of PTCHD2 in cellular signaling networks.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Inhibits the Hedgehog (Hh) signaling pathway, which Patched domain-containing protein 2 is known to be involved in, by directly binding to and inhibiting the Smoothened (Smo) receptor, resulting in the functional inhibition of Patched domain-containing protein 2 downstream signaling. | ||||||
Vismodegib | 879085-55-9 | sc-396759 sc-396759A | 10 mg 25 mg | $80.00 $96.00 | 1 | |
Directly binds to and inhibits Smoothened, a G protein-coupled receptor that is regulated by Patched domain-containing protein 2, thus inhibiting the Hh signaling pathway and the functional activity of Patched domain-containing protein 2. | ||||||
Erismodegib | 956697-53-3 | sc-396280 sc-396280A | 10 mg 100 mg | $255.00 $918.00 | ||
Targets and inhibits Smoothened, leading to the downregulation of the Hh signaling pathway activity, and as a consequence, inhibits the functional signaling of Patched domain-containing protein 2. | ||||||
GANT61 | 500579-04-4 | sc-202630 sc-202630A sc-202630B | 1 mg 5 mg 10 mg | $63.00 $128.00 $200.00 | 6 | |
Inhibits GLI transcription factors in the Hh pathway, downstream of Patched domain-containing protein 2, thus reducing the transcriptional activity driven by this pathway and functionally inhibiting Patched domain-containing protein 2 signaling. | ||||||
Saridegib | 1037210-93-7 | sc-507351 | 5 mg | $3500.00 | ||
Acts on Smoothened, inhibiting its activity and thereby inhibiting the Hh signaling pathway which Patched domain-containing protein 2 is a part of, leading to the functional inhibition of Patched domain-containing protein 2. | ||||||
SANT-1 | 304909-07-7 | sc-203253 | 5 mg | $132.00 | 5 | |
Directly inhibits Smoothened, thereby blocking Hh signaling and inhibiting the functional activity of Patched domain-containing protein 2 which acts upstream of Smoothened. | ||||||
Jervine | 469-59-0 | sc-200934 sc-200934A | 1 mg 5 mg | $66.00 $240.00 | 1 | |
Inhibits Smoothened receptor function, thereby blocking the Hh signaling pathway in which Patched domain-containing protein 2 is involved, leading to inhibition of Patched domain-containing protein 2 activity. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $76.00 $139.00 | 23 | |
Inhibits Smoothened receptor and by extension the Hh pathway, leading to the functional inhibition of Patched domain-containing protein 2 signaling activities. | ||||||
BMS 833923 | 1059734-66-5 | sc-503864 | 10 mg | $240.00 | ||
Targets and inhibits Smoothened, which is part of the Hh signaling pathway that Patched domain-containing protein 2 regulates, resulting in functional inhibition of Patched domain-containing protein 2. | ||||||
PF-5274857 | 1373615-35-0 | sc-478208 | 5 mg | $360.00 | ||
Inhibits Smoothened, which Patched domain-containing protein 2 regulates, thereby hindering the Hh signaling pathway and causing functional inhibition of Patched domain-containing protein 2. | ||||||